Navigation Links
Anakinra for rheumatoid arthritis: A modest benefit with some risk
Date:1/20/2009

New research supports a modest beneficial effect of anakinra for rheumatoid arthritis patients, but warns against potential risks for serious infections and its use with other biologic medications.

Rheumatoid arthritis is a chronic inflammatory disease affecting as many as one in 100 people worldwide. It affects the joints, making them stiff and painful. Anakinra is one of a new breed of arthritis drugs licensed in the past decade called 'biologics'. The drug is the first to target the immune protein IL-1, thought to be partly responsible for inflammation in arthritis patients. It is given by daily injection.

In a Cochrane Systematic Review of five recent anakinra trials involving 2,876 patients, researchers found anakinra reduced pain and stiffness in patients, and helped to improve joint function, when compared to placebo. However, while around a quarter of patients experienced improvement in their symptoms as a result of taking anakinra, the researchers say the improvements are notably less than those seen with other biologics.

In addition, there were more injection site reactions with the use of anakinra and the rate of serious infections with anakinra was approaching statistical significance when compared to placebo. "We would recommend caution with the use of anakinra for rheumatoid arthritis, especially with the only modest beneficial outcomes compared to other biologic medications studied for rheumatoid arthritis," said lead researcher Dr. Marty Mertens of the University of Minnesota in the US.

One study included in the review investigated the combination of anakinra with another biologic medication, etanercept. This found no benefits in arthritis outcomes, but did show a significant increase in the number of serious adverse events. "On the basis of these results, we recommend that doctors avoid combining biologic medications with anakinra when treating patients with rheumatoid arthritis,' said Mertens.

Dr. Mertens thinks more research is required to better inform patients and doctors about the safety of the drug: "We have only limited data on the safety of anakinra, and need more long-term studies to evaluate this, especially the potential for increased risk of serious infections."


'/>"/>

Contact: Jennifer Beal
wbnewseurope@wiley.com
44-012-437-70633
Wiley-Blackwell
Source:Eurekalert

Related biology news :

1. Study identifies genetic risk factor for rheumatoid arthritis, lupus
2. New Actemra data shows significant benefit for patients suffering from rheumatoid arthritis
3. Blood clotting protein linked to rheumatoid arthritis
4. Electronic switch opens doors in rheumatoid joints
5. New guidelines for treating rheumatoid arthritis
6. New therapeutic target identified for rheumatoid arthritis
7. Anything but modest: The mouse continues to contribute to humankind
8. Modest CO2 cutbacks may be too little, too late for coral reefs
9. Tufts University biologists link Huntingtons disease to health benefits in young
10. The benefits of 80 million years without sex
11. New data shows benefits of MitraClip for patients with mitral regurgitation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/9/2017)... and MOUNTAIN VIEW, Calif. ... "Eating Well Made Simple," and 23andMe , the ... guide better food choices.  Zipongo can now provide customers ... food preferences, health goals and biometrics, but also genetic ... food choices. Zipongo,s personalized food decision support ...
(Date:3/2/2017)... Summary This report provides all the ... interests and activities since 2010. ... Read the full report: http://www.reportlinker.com/p03605615-summary/view-report.html ... report provides an in-depth insight into the partnering activity of ... On demand company reports are prepared upon purchase to ensure ...
(Date:3/1/2017)... 1, 2017  Aware, Inc. (NASDAQ: AWRE), a leading ... Richard P. Moberg has resigned, effective March 3, ... Financial Officer and Treasurer of Aware citing a desire ... a member of the Board of Directors of Aware. ... Executive Officer and co-President, General Counsel has been named ...
Breaking Biology News(10 mins):
(Date:3/29/2017)... ... 29, 2017 , ... ComplianceOnline, the leading governance, risk and compliance advisory network ... Device Summit 2017 venue and speaker lineup. The Summit will take place on June ... The Omni Parker House Hotel, which is located at 60 School Street, Boston, MA ...
(Date:3/29/2017)... ... March 29, 2017 , ... Cancer diagnostics and ... booth 513 at the Association of Community Cancer Centers (ACCC) 43rd Annual Meeting, ... , CANCERSCAPE unites key stakeholders from leading national organizations to share insights on ...
(Date:3/29/2017)... Limited (TSX:GEN) ("GeneNews" or the "Company") announced today the ... for breast cancer, via its Virginia -based ... blood-based biomarker test with a sophisticated algorithm to determine a ... ... measures the fasting plasma levels of two biomarkers in the ...
(Date:3/28/2017)... ... , ... Mass spectrometry is becoming more widely for clinical testing and evaluation ... potential to perform challenging analyses in complex matrices and sample types. While mass spectrometry ... it to be routinely used for medical testing. , In this webinar, ...
Breaking Biology Technology: